Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. The aim of this review is to objectively evaluate the effects of the drug trimetazidine (TMZ) on ischemia-reperfusion injury in coronary artery bypass graft surgery by reviewing all known studies from recent years.
Introduction
Prolonged ischemia, as with the evolution of an acute myocardial infarction, coronary bypass operation, or cardiac transplantation, jeopardizes cell viability and ultimately cardiac function [1] [2] . Myocardial ischemia of limited duration, less than 20 minutes, followed by reperfusion, is accompanied by functional recovery without evidence of structural or biochemical evidence of tissue injury. Paradoxically, reperfusion of cardiac tissue, which has been subjected to an extended period of ischemia (>20 minutes), results in a phenomenon known as myocardial reperfusion injury [1] [2] [3] .
Myocardial reperfusion injury is defined as the death of myocytes, alive at the time of reperfusion, as a direct result of one or more events initiated by reperfu-sion. Therefore, myocardial cell damage results from the restoration of blood flow to the previously ischemic heart thereby extending the region of irreversible injury beyond that due to the ischemic insult alone [1] [4] [5] . Reperfusion injury may also be defined as "those metabolic, functional, and structural consequences of restoring coronary arterial flow that can be avoided or reversed by modification of the conditions of reperfusion" [3] .
The cellular damage in reperfusion injury can be reversible or irreversible, depending on the length of the ischemic insult. If reperfusion is initiated within 20 minutes after the onset of ischemia, the resulting myocardial injury is reversible and is characterized functionally by depressed myocardial contractility, which eventually recovers completely. Myocardial tissue necrosis is not detectable in the previously ischemic region although functional impairment of contractility may persist for a variable period, as myocardial stunning. Initiating reperfusion after a duration of ischemia of longer than 20 minutes, however, results in irreversible myocardial injury or cellular necrosis [1] [4] [5] .
Irreversible reperfusion myocardial injury is defined as reperfusion-induced cell death of the cardiomyocytes that were still viable at the time of blood flow restoration [1] . Thus, irreversible reperfusion injury extends the initial infarction caused by ischemia with further clinical deterioration in the shape of heart failure and arrhythmias [1] [4] [5] .
Reperfusion injury is a phenomenon which has been attracting the attention of researchers because of its evident and important repercussions in clinical cardiology practice, and has been leading to a better understanding of the events related to it, particularly as to the so-called hyperoxide radicals, that may cause injury after aorta unclamping in cardiac surgery. The hyperoxide radicals include superoxide anion ( 2 O − ), hydroxyl radical (OH), and hydrogen peroxide (H 2 O 2 ), which can be removed from the cells by systems of enzymes with antioxidant functions, typically present in the myocardial physiology [4] . These systems of endogenous enzymes with antioxidant action, as superoxide dismutase, glutathione peroxidase, and catalase, are responsible for the limitation of intracellular accumulation of 2 O − and H 2 O 2 during normal metabolism, whether by inhibiting its formation or by carrying these radicals out of the cell, reducing the oxidative damage on proteins and lipids [4] .
Seeking to improve myocardial protection during procedures that involve reperfusion injury, recent attention was turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. With its cytoprotective mechanism, TMZ limits calcium accumulation and intracellular acidosis, inflammation and hyperoxide free radicals production that occur after reperfusion, without provoking hemodynamic alterations. Its use in ventricular dysfunction prophylaxis has also demonstrated a beneficial action on the "stunned myocardium", a clinical translation of the injury over the ventricular function after myocardial revascularization surgery [5] [6] [7] .
Mechanisms of Ischemia-Reperfusion Injury
The major mechanisms of myocardial reperfusion injury are the absence of normal oxidative phosphorylation (Figure 1 ), oxidative stress (predominantly oxygen-free radicals), neutrophil-endothelium interactions, apoptosis, and calcium overloading [7] . It is unlikely that any single pathophysiologic mechanism of myocardial reperfusion injury causes lethal myocardial injury. When multiple pathologic events occur simultaneously, injury is an additive and the probability of irreversible myocardial injury occurring increases significantly [7] . Prolonged ischemia causes the absence of normal oxidative phosphorylation and diminished myocardial tissue concentrations of adenosine 5-triphosphate (ATP) and creatine phosphate within the mitochondria, which leads to ultrastructural changes [8] [9] . Initially, when ATP use exceeds the capacity of the myocytes to resynthesize high-energy phosphates, degradation of adenine nucleotides results in the conversion of adenosine diphosphate (ADP) to adenosine monophosphate (AMP) [8] . Further sustained reductions in ATP availability result in irreversible myocyte injury associated with sarcolemmal damage, acidosis, and cellular swelling [8] . Myocardial ischemia is further associated with an accumulation of intracellular lactic acid [10] and a decline in fatty-acid oxidation, which normally provides 60% to 90% of myocardial energy requirements [11] .
Oxidative Stress
The oxygen paradox hypothesis is based upon the basis that oxygen can inflict Figure 1 . Oxidative balance Brasileiro (1997, p. 84). World Journal of Cardiovascular Surgery injury to the ischemic myocardium during reperfusion [5] . Upon reperfusion, myocytes go from a hypoxic state to normal oxygen tension very rapidly, thus initiating the sequential reduction of O 2 resulting in reactive oxygen species production [5] [12] . Cells that encounter the reactive oxygen species (ROS) undergo oxidative damage as the ROS becomes more stable at the expense of nearby molecules in contact. Under physiologic conditions, small quantities of ROS are formed during mitochondrial respiration, but they can be detoxified by endogenous scavenging mechanisms [13] . After reperfusion many scavenging molecules are "washed out" of the areas in which ROS protection is critically needed [14] [15] . Normally, hypoxanthine produced from AMP metabolism is further metabolized by xanthine dehydrogenase (XD) to xanthine [16] . During ischemia, however, XD is converted to xanthine oxidase (XO) by calcium (Ca 2+ ) dependent proteases (Figure 2 
Calcium Overload Theory
The initiation and upshot of the action potential in myocardium is derived from the entry of sodium ions (Na + ) across the sarcolemma in a positive feedback necrosis factor-alpha (TNF-α), neutrophil-activating peptide, and platelet activating factor [7] .
Neutrophils contribute to myocardial reperfusion injury by the production of ROS, proteolytic enzymes and cytokines, endothelial dysfunction, capillary plugging, and direct myocyte injury [21] [23]. Neutrophils also cause coronary vascular constriction, which can decrease cardiac performance [24] . Through a process called "no-reflow", aggregating neutrophils can occlude microvessels and increase capillary blood flow resistance, causing microcirculatory ischemia and even tissue infarction [25] . No-reflow is defined as severe microvascular dysfunction that limits perfusion during reperfusion [26] .
Endothelial dysfunction occurs in the first 2.5 to 5 minutes of reperfusion.
The effects of endothelial dysfunction include platelet and neutrophil activation, vasoconstriction, increased ROS production, and increased protein and fluid extravasation [26] .
Mitochondrial Dysfunction and Apoptosis
Mitochondrial permeability transition pore (MPTP), mitochondrial dysfunction and apoptosis.
Normally, the respiratory chain releases only small amounts of ROS pre-dominantly by complex I. During early reperfusion, ROS formation from various sources, including the respiratory chain, is largely augmented. Mitochondrial complexes I and III are major sources of pathological ROS production. The MPTP is a large-conductance mega-channel putatively constituted by the voltage-dependent anion channel in the outer membrane, the adenine nucleotide transporter in the inner membrane, and cyclophilin D in the matrix. Under physiological conditions, MPTP is predominantly in a closed state [27] . The opening of the MPTPs causes the disruption of the inner mitochondrial membrane. The membrane will lose its potential, a depletion of the mitochondrial nicotinamide adenine dinucleotide (NADH) pool will occur, and the oxidative phosphorylation will be uncoupled leading to accelerating a source of ROS, and can lead to World Journal of Cardiovascular Surgery further cascade reactions with fatal cell injuries as a consequence. The early opening of the MPTPs also activates the mitochondrial apoptosis cascade which is yet another mechanism for accelerated cell death following ischemia and reperfusion [28] .
Trimetazidine
Trimetazidine, [1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride](TMZ) (Figure 3) , is a metabolic anti-ischemic drug that exerts its beneficial effects without altering the hemodynamic function of the heart [29] . The mechanism of action of trimetazidine is related to the optimising cardiac metabolism by reducing fatty acid oxidation through the selective inhibition of mitochondrial 3-ketoacyl CoA thiolase, which is critical to the b-oxidation pathway. As a result, TMZ decreases ischemic stress and improves cardiac performance during ischemia [30] . This inhibition decreases the utilisation of free fatty acids as a source of energy for the myocardium, resulting in an increase in glucose oxidation ( Figure 4 ). This metabolic switch acts to improve cardiac energy metabolism by switching ATP production from lipid to glucose oxidation, thus enhancing intramitochondrial coupling and favouring a more efficient mode of ATP production per mole of oxygen [29] [30] . At the cellular level, TMZ preserves ATP production and reduces intracellular acidosis and calcium overload and thereby maintains the cellular homeostasis [30] . TMZ decreases oxidative damage to mitochondria and protects hearts from I/R-induced damage to mitochondrial respiration [31] . TMZ also showed a cytoprotective effect in several models of myocardial infarction [32] [33] . Recently, it has been shown that TMZ protected post-ischemic hearts by inhibiting the activation of neutrophils [34] . 
TMZ in Coronary Artery Bypass Grafting Cardiosurgery
There are still only a few studies suggesting the role of TMZ in patients subjected to coronary artery bypass grafting (CABG) in the last 10 years. However, according to the studies with reperfusion protection effects of TMZ in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and anti-ischemic role during stable angina confirmed in guidelines, the application of TMZ in patients undergoing surgical revascularization seems to be completely justified [35] .
Nowadays the chronic coronary disease has good evidence in their treatment, supported by guidelines and meta-analysis of randomised double-blind trials.
The group of patients treated with PTCA after aggressive medical therapy and TMZ, showed less ST elevation and significant lower mean (P < 0.05) and maximal amplitude of T wave alteration. The trimetazidine administered before angioplasty is sustained by few randomised studies with good myocardial protection [36] .
Finally, in the first randomised, double-blind, placebo-controlled study, developed in 1992, Fabiani et al. [37] evaluated the role of TMZ in the prevention of disadvantageous effects of ischemia-reperfusion injury in patients subjected to heart surgery. Nineteen patients (10 in TMZ group, and nine in the control group) who underwent CABG were included in the study. TMZ was started at 20mg, three times daily orally for three weeks before the surgery and the same drug was added to the cardioplegic solutions [37] . Metabolic measurements [40] . However, this study had many limitations, so the results should be confirmed in future studies, as pointed out in comments after publication. Later we will review the protective properties of TMZ in patients with normal or mildly dysfunctional ventricle in the study of Martins et al.
2011 [41] .
Three years later Turnerir et al. (1999) [42] observed the cardioprotective role of TMZ. The authors evaluated potential myocardial protection of TMZ by measurement of troponin t (TnT) during CABG. Thirty randomised patients were included in this double-blind study. The TMZ group was composed of 15 patients in New York Heart Association (NYHA) class III or IV. Pretreatment was started three weeks before CABG with TMZ (60 mg orally per day) or placebo. The pre-operative serum concentration of TnT levels were 0 to 0.39 ng/mL in all patients. The mean TnT levels were measured five mins after completion of cardiopulmonary bypass and 12, 24 and 48 h post-operatively in the placebo and TMZ groups. The result shows that in the TMZ group, TnT levels were significantly lower than those in the placebo group at all times (p = 0.001). The authors concluded that pretreatment with TMZ significantly reduces ischemic-reperfusion damage during CABG [42] . Nevertheless we should attempt to quantify these results, evaluated in clinical improvement of the patients and performing the action which allows analysis of the outcomes and its relation to the pretreatment conduced with trimetazidine.
Kuralay et al. (1999) [43] evaluated the effect of trimetazidine and diltiazem on persistent myocardial ischemia after coronary artery bypass graft surgery in the prospective randomised study. Sixty patients were divided into three groups of 20 each and followed up for 12 months. Patients in all three groups received acetylsalicylic acid 100 mg per day, those in group one also had trimetazidine 60 mg per day, and those in group two had diltiazem 90 mg per day. Each patient had coronary angiography during the first three weeks after surgery, 24-hour ambulatory monitoring every month, and cardiac scintigraphy at three weeks, six months, and 12 months. Perfusion defects had resolved in the trimetazidine group at six months. At 12 months, perfusion defects had resolved in the diltiazem group but not in the group receiving only acetylsalicylic acid (p < 0.05). Based on these results it seems that trimetazidine is superior to diltiazem in resolving the myocardial perfusion defects at six months after coronary artery bypass surgery [43] .
Ruzyllo et al. (2004) showed by retrospective analysis of a subgroup of 94 patients from the TRIMPOL II study that trimetazidine provides anti-anginal efficacy in post-revascularized patients with recurrent angina despite a monotherapy with metoprolol [44] . World Journal of Cardiovascular Surgery injury. The aim of this study was to determine whether trimetazidine could reduce myocardial reperfusion injury damage in coronary artery bypass graft surgery (CABG) using evolutive serial troponin T and creatine kinase isoenzyme MB (CPK-MB) blood levels and to verify possible follow-up changes in left ventricular (LV) echocardiographic function, and also the frequency of the ventri-World Journal of Cardiovascular Surgery cular fibrillation at the end of bypass. The authors conduced a double-blind, placebo-controlled study on 60 randomised patients who underwent CABG. The TMZ and the placebo group were composed of 30 patients each, stratified by echocardiography to include only patients with normal and/or mild LV dysfunction and receiving medication/placebo at a dose of 20 mg three times a day, starting from 12 to 15 days after a pre-operative period of up to five to eight days after the post-operative period. Troponin T and CPK-MB were measured pre-operatively without medication, 12 to 15 days of medication/placebo taken five minutes after aortic declamping, and at subsequent 12, 24 and 48 hours. The echocardiographic measurements were performed: pre-operative without medication, on the day of surgery with the use of 10 days of medication/placebo, and after leaving the ICU with at least 15 days of medication/placebo. The ventricular fibrillation was verified through cardioscopic and direct transthoracic observation at the end of bypass. The results of TnT and CPK-MB reached highly significant values (p = 0.0001) in the treated group compared to the control group at the four points when analysed-five mins, 12 h, 24 h and 48 h. The echocardiographic variables did not show evolutive changes in each group which were considered and compared between themselves. The frequency of ventricular fibrillation at the end of bypass was low in both groups. The authors conclude that pretreatment with trimetazidine reduces ischemic-reperfusion damage during CABG, but did not affect LV echocardiographic variables [41] .
In the latter trial to present, Lopatin and Dronova (2009) [47] could add the greatest number of patients in these last 10 years of study, as well as the longer period of follow-up and using a new presentation of trimetazidine (35 mg/MR per tablet) evaluating clinical and pharmacoeconomic effects of long-term use of trimetazidine MR in 306 patients undergoing coronary artery bypass grafting (CABG). Six hours after CABG serum creatine Kinase and creatine-Kinase MB were significantly lower in the group using trimetazidine during two weeks prior to surgery. The rate of ischemic events was also lower in this patients and the long-term use of trimetazidine MR improve left ventricular systolic function and exercise tolerance [47] .
Recently, in a randomised double-blind prospective study, controlled with placebo, the effects of trimetazidine (TMZ) on the inflammatory response were analysed. The changes in inflammatory response were analysed by using the variation in the levels of leukocytes, neutrophils and monocytes, and also in the 
Conclusion
There are still only a few studies suggesting the role of TMZ in patients subjected to CABG. However, we can verify that the meta-analyzes prove the action of the drug in the protection of the cardiac cell with improvement of the symptoms in- 
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